EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced participation in several upcoming conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, the Stifel 2022 Healthcare Conference on November 16, 2022, and BTIG Ophthalmology Day on November 29, 2022. Webcasts of these presentations will be available for replay on the company's website. EyePoint focuses on therapeutics for serious eye disorders, leveraging its Durasert® technology, including EYP-1901, currently in Phase 2 trials.

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

• Guggenheim 4^th Annual Immunology and Neurology Day
  Forum: Fireside Chat
  Date: Monday, November 14, 2022
  Time: 3:20 p.m. ET

• Stifel 2022 Healthcare Conference
  Forum: Corporate Presentation
  Date: Wednesday, November 16, 2022
  Time: 3:00 p.m. ET

• BTIG Ophthalmology Day
  Forum: Fireside Chat
  Date: Tuesday, November 29, 2022
  Time: 2:00 p.m. ET

A webcast and subsequent archived replay of each corporate presentation, when available, may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:
Christina Tartaglia
Stern IR
Direct: (212)-698-8700
christina.tartaglia@sternir.com 

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com 

FAQ

What conferences will EyePoint Pharmaceuticals participate in during November 2022?

EyePoint Pharmaceuticals will present at the Guggenheim 4th Annual Immunology and Neurology Day on November 14, Stifel 2022 Healthcare Conference on November 16, and BTIG Ophthalmology Day on November 29, 2022.

What is EYP-1901 and its current status?

EYP-1901 is an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials.

Where can I access the webcast of EyePoint Pharmaceuticals' conference presentations?

You can access the webcast and archived presentations on the Investors section of EyePoint Pharmaceuticals' website.

What technology does EyePoint Pharmaceuticals use for drug delivery?

EyePoint Pharmaceuticals leverages its proprietary Durasert® technology for sustained intraocular drug delivery.

When is the Guggenheim conference presentation scheduled?

The Guggenheim 4th Annual Immunology and Neurology Day presentation is scheduled for November 14, 2022, at 3:20 p.m. ET.